IDO1 and cancer: Still, researchers have shown that different therapeutic combinations may subvert the failure of clinical trials, pointing that IDO inhibitors should not be abandoned for cancer immunotherapy (clinical trial information: NCT01961115, NCT02077881) (26, 27).